Therapeutic efficacy of dose-reduced adjuvant chemotherapy with S-1 in patients with pancreatic cancer: a retrospective study

• Published in: BMC cancer 2022-09, Vol.22 (1), p.1028-1028, Article 1028
• Main Authors: Kobayashi, Kazuki, Einama, Takahiro, Takihata, Yasuhiro, Yonamine, Naoto, Fujinuma, Ibuki, Tsunenari, Takazumi, Kouzu, Keita, Nakazawa, Akiko, Iwasaki, Toshimitsu, Ueno, Hideki, Kishi, Yoji
• Format: Article
• Language: English
• Subjects: Adenocarcinoma; Adjuvant chemotherapy; Adjuvant treatment; Age; Biomarkers; Cancer; Carcinoma, Pancreatic Ductal - pathology; Care and treatment; Chemotherapy; Chemotherapy, Adjuvant; Diagnosis; Humans; Lymph nodes; Medical prognosis; Metastases; Multivariate analysis; Neoplasm Recurrence, Local - drug therapy; Pancreatic cancer; Pancreatic Neoplasms; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - pathology; Pancreatic Neoplasms - surgery; Patients; Prognosis; Relative dose intensity; Retrospective Studies; S-1; Surgery; Survival; Total dose intensity; Tumors; Variance analysis
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-022-10116-2

S-1 adjuvant chemotherapy is the standard treatment in Asia for resectable pancreatic ductal adenocarcinoma. The relative dose intensity of adjuvant chemotherapy influences survival in pancreatic cancer but does not precisely reflect treatment schedule modifications. We investigated the effects of total dose intensity of S-1 adjuvant chemotherapy on the survival of patients with pancreatic cancer and the permissible dose reduction. Patients who underwent surgical resection during 2011-2019 for pancreatic cancer were selected. We determined the total dose intensity cut-off value that predicted tumor recurrence within 2 years postoperatively using receiver operating characteristic curves and compared the outcomes between the high and low total dose intensity groups. Patients with total dose intensity ≥ 62.5% (n = 53) showed significantly better overall survival than those with total dose intensity